Daily Posts Archive

Standard & Poor’s lists a whopping 196 biotechnology companies in its database, but AbbVie (ABBV) stands out above the rest. The company is growing rapidly but due to the correction in biotech stocks, it’s now an undervalued stock.

Both professional and novice investors sometimes forget that the objective is to make money, not to own every good-looking stock in the market.

Investors continue to cycle in and out of different sectors, and biotech stocks are next in line to benefit from that sector rotation.

While small-cap dividend stocks don’t always make for juicy storylines, the fact is that many of the best performers in the stock market today are these little income producers. And if you have the willpower to stick with them, you may easily find their performance rivals that of the best performing growth stocks. Here are three stocks for your review.

What is the difference between emerging markets stocks, developing markets stocks and frontier markets stocks? It depends on who you ask. There is no universally accepted definition. In general, an emerging market is one that is close to becoming a developed one—the developed ones being all of the major European countries, plus the U.S., Canada, Japan, Australia and New Zealand.

Here it is, in just 10 words: Market goes up, get in. Market goes down, get out.

When seeking better-than-average growth, many investors flock to emerging markets. And in emerging markets investing, Chinese stocks are your best bet.

Many experts says 30% of your equity portfolio should be invested internationally.

These tools are based on what has worked over and over again in the past 50 years.